Hepatocellular Carcinoma
Conditions
Interventions
Case series:continuous hepatic artery infusion of oxaliplatin combined with retitrexide
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. patients with liver cancer diagnosis of AASLD and EASL HCC; 2. based on the guidelines for the management of patients should be treated with conventional transcatheter arterial chemoembolization for patients with stage C or BCLC for intrahepatic diffuse multiple lesions and conventional chemoembolization therapy expected arteriovenous fistula in patients with BCLC B; 3. patients. Before local treatment such as TACE, RFA, radiotherapy, or systemic therapy such as molecular targeted drug therapy (Sola Feeney, apatinib etc.), intravenous chemotherapy, can also be incorporated in the study, as long as the focus of premenstrual treatment has no progress, the local treatment indications. In addition to patients when they entered the study period the treatment should be stopped for more than 4 weeks. The patients in surgery after recurrence and no TACE treatment indications can also be incorporated into the tumor stage. Based on the hepatic arterial infusion chemotherapy of tumor present situation; 4. the patient's should be between the ages of 18-75 years of bone; 5. Spinal cord function (Hb = 10 g/dL, WBC = 3000/ L, platelet count or 75000/L), liver function (serum bilirubin = 3mg/dL, U/L = 200), renal function (creatinine less than or equal to 390 Mu mol /L). The coagulation function is basically normal; 6. the PS score of 2 or less; 7. can obtain informed consent of patients or their families.
Exclusion criteria
Exclusion criteria: 1. decompensation of liver function (including ascites uncontrolled, hepatic encephalopathy); 2. Acute or recent Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage / Gastrointestinal Hemorrhage within 2 weeks; 3. extensive extrahepatic metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response; | — |
Countries
China
Contacts
Public ContactYu Wenchang
Department of Interventional Oncology, Fujian Cancer Hospital
Outcome results
None listed